One of the portfolio firms of San Diego-based venture capital firm Enterprise Partners, Complete Genomics is set to debut on the market Thursday, after pricing its IPO this evening. According to a filing from Complete Genomics, it will sell 6 million shares at $9.00 per share, below an earlier estimated range of $12.00 to $14.00 per share for the company. Complete Genomics will trade on the NASDAQ Global Market as GNOM. Enterprise Partners owns about 14.8 percent of Complete Genomics. The IPO marks the second major acquisition in Enterprise Partners' portfolio this year; the firm also was an investor in Targegen, which was acquired by Sanofi-aventis in June.
Top NewsWednesday, November 10, 2010
Enterprise Partners Portfolio Firm Heads To Market